Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Cash And Cash Equivalents : $944.1 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Cash And Cash Equivalents?

Ginkgo Bioworks Holdings's quarterly cash and cash equivalents declined from Jun. 2023 ($1,105.79 Mil) to Sep. 2023 ($1,049.24 Mil) but then stayed the same from Sep. 2023 ($1,049.24 Mil) to Dec. 2023 ($944.07 Mil).

Ginkgo Bioworks Holdings's annual cash and cash equivalents declined from Dec. 2021 ($1,550.00 Mil) to Dec. 2022 ($1,315.79 Mil) and declined from Dec. 2022 ($1,315.79 Mil) to Dec. 2023 ($944.07 Mil).

Ginkgo Bioworks Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Cash And Cash Equivalents Chart

Ginkgo Bioworks Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

380.80

1,550.00

1,315.79

944.07

Ginkgo Bioworks Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial										1,315.79	1,206.09	1,105.79	1,049.24	944.07

Ginkgo Bioworks Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ginkgo Bioworks Holdings (NYSE:DNA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ginkgo Bioworks Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

DNA.WS:USA DNA:Mexico

Address

27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210

Website

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.

Executives

Jason R Kelly	director, officer: CEO & Founder	667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk	officer: Chief Financial Officer	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton	10 percent owner	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty	director, 10 percent owner, officer: President, COO & Founder	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan	director, officer: CEO, Chairman	1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar	director	C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan	director	ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830